New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
07:11 EDTPOZNPOZEN upgraded to Strong Buy from Buy at Ascendiant Capital
Ascendiant Capital upgraded POZEN with an $8.25 price target citing the recent pullback in shares.
News For POZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
07:42 EDTPOZNPOZEN receives three patents from USPTO
POZEN (POZN) announced that it has received three patents from the United States Patent and Trademark Office, entitled “Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs” that cover the U.S. approved product VIMOVO. All three patents are expected to expire in 2022. Horizon Pharma (HZNP), which holds the U.S. NDA for VIMOVO, and POZEN plan to list U.S. patents 8,858,996 and 8,852,636 in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use